ABC transporter expression to predict therapeutic effect of enfortumab vedotin in urothelial cancer.

Hiroki Shimoda,Atsuko Takada-Owada,Toshiki Kijima,Hidetoshi Kokubun,Toshitaka Uematsu,Kohei Takei,Yoshimasa Nakazato,Masahiro Yashi,Kazuyuki Ishida,Takao Kamai

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.693

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:693 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of anti-Nectin-4 antibody and is approved for metastatic urothelial cancer. Predictors of therapeutic benefit of EV have not been established since nectin-4 expression varies widely with the course of treatment. ATP Binding Cassette (ABC) transporters which export the administered anti-cancer drugs out of the cells have been postulated as one of the mechanisms of therapeutic resistance to EV. In this study, we evaluated the expression of Nectin-4 and ABC transporters in primary biopsy tissues, primary radical resection tissues, and metastatic sites from urothelial cancer patients and evaluated their association with prognosis after EV therapy. Methods: We studied 16 patients who received enfortumab vedotin for metastatic urothelial cancer. Biopsy of primary tissue, radical surgery of primary tumor, and resection of metastatic sites was performed in 16, 7, and 4 patients, respectively. In these specimens, the expression of nectin-4 and ABC transporters was evaluated by immunostaining. Among ABC transporters, we evaluated MDR1 (ABCB1), MRP1 (ABCC1), and BCRP (ABCG2) since they have been reported to be associated with anticancer drug resistance. Staining intensity on the cell membrane was classified into 0 to 3 according to the evaluation criteria of HER2. We investigated the relationship between the expression of nectin-4 and ABC transporters and survival after EV therapy. Results: Nectin-4 was positive in all patients (score 3 in 12 patients, score 1 in 4 patients) in primary biopsy. All patients tested negative for MDR1. MRP1 was positive in 11 (score 2 in 2 patients and score 1 in 9 patients), and BCRP was positive in 14 (score 2 in 10 patients, score 1 in 4 patients). Nectin-4 expression decreased in radical surgery tissues and metastatic sites. On the other hand, ABC transporter expression remained unchanged or rather increased in radical surgery tissues and metastatic sites (Table). Patients with both MRP1 and BCRP expression in the primary biopsy specimen (n=8) had significantly worse PFS and OS after EV therapy while nectin-4 expression in the primary biopsy specimen was not associated with survival. Conclusions: Patients with ABC transporter expression had a poor prognosis after EV therapy, although nectin-4 expression in primary biopsies was not associated with prognosis. Nectin-4 expression tended to decrease, while the ABC transporter remained unchanged or enhanced as the disease progressed. [Table: see text]

oncology